Pacific GeneTech Progresses Its US Headquarters Facility

​

​

​

1 March 2023

​

 

Pacific GeneTech reports that it is progressing the development of its new US headquarters facility in Northwest Arkansas. The facility is currently under development and is expected to be completed in Q4 this year. The facility will include the company’s corporate headquarters, a manufacturing suite for its Hercules adjuvant and an R&D laboratory.

 

 

ABOUT PACIFIC GENETECH

​

Pacific GeneTech (www.pacificgenetech.com) develops and commercializes next-generation vaccines and biologics for areas of high unmet or underserved needs in food safety and animal health. PGT's proprietary "Aegis" vaccine platform combines cross-protective antigens and immunopotentiators in PGT vectors for broad spectrum protection against multiple strains and species of infectious diseases. The PGT vaccines can be administered orally or by injection in both live and inactivated forms. PGT's "Hercules" adjuvant/delivery system provides enhanced efficacy of inactivated vaccines and its yeast vector is a safe, flexible and robust carrier of immunogenic material.

 

PGT has out-licensed two of its leading poultry vaccines addressing economically important gastro-intestinal pathogens and has out-licensed its Hercules adjuvant for use in third-party vaccines. Vaccines for other pathogens and animal species are under development. PGT is developing other applications for its Hercules adjuvant delivery system and for the yeast vector. PGT, through its affiliate company, PGTx, has commenced programs with collaborators addressing human dysentery.

​

​